Radar · Infectious Diseases in California
Best Infectious Diseases Companies in California, United States
The 238 best Infectious Diseases companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Brii Biosciences.
By Riya SenguptaFinancials
238companies tracked
$6.8Bdisclosed funding
0unicorns
154have raised
FLIAR INTELLIGENCE · INFECTIOUS DISEASES × CALIFORNIA
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
59%cloud-native stacks
2025funding peak (by rounds)
1unicorns
2014median founding year
252kcombined LinkedIn audience
29%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Infectious Diseases companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Brii Biosciences Developer of biologics to treat hepatitis B infection | $515M | 57 mo ago | 68 68 → 83 (+22%) · sector median +22% | 2018 | Zhi Hong Co-Founder & CEO | 106 patents Antiviral nucleoside analogs/capsid inhibitors and neurosteroid-based CNS therapeutics | — |
| 2 | Karius Provider of diagnostics for identifying infectious diseases using microbial DNA | $315M | 25 mo ago | 139 139 → 212 (+53%) · sector median +22% | 2014 | Tim Blauwkamp Chief Scientific Officer | 81 patents Rapid metagenomic sequencing workflows for pathogen detection and microbial biomarker analysis. | — |
| 3 | Vaxcyte Developer of vaccines to treat infectious diseases | $281M | 74 mo ago | 254 254 → 563 (+122%) · sector median +22% | 2013 | Jeff Fairman Co-Founder & VP | 124 patents Vaccine antigen‑polysaccharide conjugates and purification processes for immunogenic biologics | 2 awards |
| 4 | Bluejay Therapeutics Developer of therapeutics for the treatment of infectious diseases | $243M | 25 mo ago | 3 | 2019 | Keting Chu Founder | — | — |
| 5 | Aligos Therapeutics Developer of therapies to treat hepatologic diseases and viral infections 50Patents top 12%Innovation top 16%Funding top 26%Moat top 35% All 12 signals ▾Patentstop 12% Innovationtop 16% Fundingtop 26% Moattop 35% Partnerstop 40% Techtop 42% Talenttop 45% Globaltop 46% Newstop 47% Marketbottom 46% Growthbottom 32% Fin. healthbottom 25% Patents: 503 patents matched (strict assignee match) · 389 filings since 2022 vs 114 in 2017-21 Innovation: 503 patents (top 5% of patent-holders) · 389 filings since 2022 vs 114 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $225M | 16 mo ago | 70 70 → 99 (+41%) · sector median +22% | 2018 | Lawrence Blatt CEO | 503 patents RNA interference therapeutics and PD‑L1 immuno‑oncology using heterocyclic siRNA delivery compounds | — |
| 6 | MicuRx Pharmaceuticals Develops antibiotics against multidrug-resistant (MDR) superbug infections | $225M | 65 mo ago | 4 | 2007 | Zhengyu Yuan Co-Founder & CEO | — | — |
| 7 | NovaBay Pharmaceuticals Developer of eye care and wound care products 32Funding top 21%Product top 35%News top 46%Talent bottom 49% All 10 signals ▾Fundingtop 21% Producttop 35% Newstop 46% Talentbottom 49% Moatbottom 44% Marketbottom 43% Techbottom 41% Growthbottom 40% Globalbottom 38% Fin. healthbottom 37% Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Product: 0 product launch events in 12 mo · Company stage: Public rank vs industry peers · Fliar Intelligence Index 32/100 | $220M | 5 mo ago | 33 33 → 38 (+15%) · sector median +22% | 2000 | Justin Hall CEO | — | — |
| 8 | Vir Biotechnology Developer of therapeutics for the treatment of infectious diseases | $216M | 73 mo ago | 417 417 → 471 (+13%) · sector median +22% | 2017 | Klaus Frueh Co-Founder | 423 patents Broadly neutralizing antiviral antibodies and combination therapies for hepatitis B and respiratory viruses | — |
| 9 | PaxVax Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others. | $212M | 126 mo ago | 138 | 2007 | — | 27 patents Adenoviral vector vaccine platforms and spray‑drying formulation technologies for infectious disease vaccines | — |
| 10 | CytoVale Microfluidic-based biomarkers for the early detection of sepsis 60Funding top 19%Product top 21%Patents top 26%Innovation top 32% All 10 signals ▾Fundingtop 19% Producttop 21% Patentstop 26% Innovationtop 32% Moattop 32% Techtop 38% Growthtop 47% Marketbottom 42% Globalbottom 42% Newsbottom 21% Funding: Raised $207M across 14 rounds · 14 rounds over 13 yrs (1.1/yr) Product: 4 distinct product lines · Company stage: Series D rank vs industry peers · Fliar Intelligence Index 60/100 | $207M | 20 mo ago | 58 58 → 120 (+107%) · sector median +22% | 2013 | — | 38 patents Point-of-care diagnostic platforms for immune activity and sepsis monitoring | — |
| 11 | Inflammatix Provider of diagnostic solutions for systemic infections 74Funding top 17%Patents top 22%Growth top 26%Innovation top 27% All 10 signals ▾Fundingtop 17% Patentstop 22% Growthtop 26% Innovationtop 27% Moattop 28% Talenttop 35% Techtop 43% Marketbottom 45% Globalbottom 42% Newsbottom 18% Funding: Raised $191M across 11 rounds · 11 rounds over 9 yrs (1.2/yr) Patents: 52 patents matched (strict assignee match) · 36 filings since 2022 vs 16 in 2017-21 rank vs industry peers · Fliar Intelligence Index 74/100 | $191M | 21 mo ago | 54 54 → 75 (+39%) · sector median +22% | 2016 | Jonathan Romanowsky Co-Founder and Chief Business Officer | 52 patents Patents concentrated in chemistry & materials | 1 launch · 2 partnerships |
| 12 | Ansun BioPharma Developer of anti-viral therapies for respiratory viruses | $191M | 80 mo ago | 34 | 2003 | — | 192 patents Gamma‑delta T‑cell manufacturing platforms and antiviral biologics for influenza therapy | — |
| 13 | Cerus Provider of pathogen inactivation technology for blood center or hospital blood bank | $159M | 76 mo ago | 247 247 → 386 (+56%) · sector median +22% | 1991 | — | 326 patents Pathogen inactivation and processing technologies for blood and biological fluid products | 1 job opening |
| 14 | Amplyx Pharmaceuticals Pharmaceutical company focused on innovative medicines, vaccines, and expanded access programs | $144M | 77 mo ago | 15 | 2006 | Mike Grey CEO | — | — |
| 15 | Clear Labs Provider of food safety technologies for the identification of pathogens 60Patents top 19%Funding top 22%Innovation top 28%Moat top 28% All 10 signals ▾Patentstop 19% Fundingtop 22% Innovationtop 28% Moattop 28% Growthtop 32% Talenttop 41% Globalbottom 44% Marketbottom 40% Techbottom 33% Newsbottom 21% Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $141M | 18 mo ago | 55 55 → 85 (+55%) · sector median +22% | 2014 | Sasan Amini Co-Founder & CEO | 79 patents Automated liquid handling and cartridge systems for nucleic‑acid sequencing sample preparation | — |
| 16 | Antiva Biosciences Developer of therapeutic drugs for sexually transmitted diseases | $125M | 37 mo ago | 21 | 2012 | Kristine Ball CEO | — | — |
| 17 | Kate Therapeutics Developer of AAV-based gene therapies to treat genetically defined muscle disease | $124M | 25 mo ago | 46 | 2020 | — | — | — |
| 18 | Osteal Therapeutics Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections 29Funding top 19%Moat top 38%Talent bottom 49%Global bottom 37% All 5 signals ▾Fundingtop 19% Moattop 38% Talentbottom 49% Globalbottom 37% Marketbottom 31% Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $111M | 8 mo ago | 13 | 2013 | David Thompson Chairman and Chief Executive Officer | — | 9 job openings |
| 19 | Evofem Developer of sexual and reproductive health therapeutics 50Funding top 24%Product top 30%Moat top 38%Patents top 43% All 12 signals ▾Fundingtop 24% Producttop 30% Moattop 38% Patentstop 43% Fin. healthtop 46% Innovationtop 48% Markettop 49% Growthbottom 49% Talentbottom 49% Techbottom 43% Newsbottom 41% Globalbottom 40% Funding: Raised $100M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 11 mo ago | 126 | 2009 | Saundra Pelletier CEO ► Phexxi ► Solosec | 60 patents Vaginal film drug delivery systems for contraception, STI prevention, and antimicrobial microbicides | 1 partnership |
| 20 | AN2 Therapeutics Developer of drugs for treating infectious disease 45Funding top 19%Talent top 38%Moat top 48%Market bottom 42% All 6 signals ▾Fundingtop 19% Talenttop 38% Moattop 48% Marketbottom 42% Globalbottom 32% Newsbottom 24% Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $92M | 3 mo ago | 35 35 → 37 (+6%) · sector median +22% | 2017 | Eric Easom Co-Founder & CEO & President | — | — |
| 21 | Cidara Therapeutics Developer of novel anti-infectives for infectious diseases (bacterial and fungal) | $78M | 18 mo ago | 90 90 → 48 (-47%) · sector median +22% | 2013 | Jeff Stein CEO | 275 patents Antibody‑drug conjugates and biologics targeting viral and cancer pathways. | — |
| 22 | Dynavax Developer of products to prevent and treat infectious and inflammatory diseases and cancer | $74M | 57 mo ago | 408 408 → 287 (-30%) · sector median +22% | 1996 | Ryan Spencer CEO | 2 patents Synthetic immunostimulatory oligonucleotides for vaccine adjuvant and therapeutic use | — |
| 23 | Armata Pharmaceuticals Developer of phage therapeutics | $73M | 50 mo ago | 69 69 → 74 (+7%) · sector median +22% | 1989 | Deborah Birx CEO | — | — |
| 24 | Gritstone bio Developer of immunotherapies for cancers and infectious diseases | $65M | 32 mo ago | 231 | 2015 | Andrew Allen President | 275 patents Immunotherapy platforms: neoantigen vaccines, multi-specific antibodies, and viral vaccine technologies. | — |
| 25 | Aridis Pharma Provider of human monoclonal antibodies against infectious diseases | $42M | 41 mo ago | 34 | 2005 | Vu Truong Founder & CEO | — | — |
| 26 | Lumos Diagnostics Provider of rapid point-of-care diagnostic test solutions 57Funding top 25%Partners top 31%News top 34%Growth top 38% All 8 signals ▾Fundingtop 25% Partnerstop 31% Newstop 34% Growthtop 38% Markettop 48% Moattop 48% Techbottom 46% Globalbottom 44% Funding: Raised $40.0M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals rank vs industry peers · Fliar Intelligence Index 57/100 | $40M | 2 mo ago | 55 | 2017 | — | — | 1 partnership |
| 27 | AusperBio Developer of therapies for the treatment of chronic hepatitis B and other major infectious diseases 40Funding top 26%Talent top 38%Moat top 39%Growth bottom 42% All 7 signals ▾Fundingtop 26% Talenttop 38% Moattop 39% Growthbottom 42% Marketbottom 40% Globalbottom 38% Newsbottom 24% Funding: Raised $37.0M across 4 rounds · 4 rounds over 2 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $37M | 8 mo ago | — | 2019 | Guofeng Cheng Co-Founder & CEO | — | — |
| 28 | Delve Bio Developer of sequencing platform to detect neuro-infectious pathogens | $35M | 35 mo ago | 2 | 2022 | Bradley Murray Founder & CEO | — | — |
| 29 | Affinity Biosensors Developer of rapid antimicrobial susceptibility testing devices for life sciences 27Funding top 27%Moat top 31%Talent bottom 49%Patents bottom 46% All 7 signals ▾Fundingtop 27% Moattop 31% Talentbottom 49% Patentsbottom 46% Innovationbottom 39% Globalbottom 36% Marketbottom 34% Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $31M | 3 mo ago | 21 | 2006 | Ken Babcock CEO | 12 patents Rapid antimicrobial susceptibility testing via resonant mass and microchannel sensor technologies | — |
| 30 | Hallux Provider of subungual drug delivery technology for onychomycosis | $27M | 37 mo ago | 4 | 2012 | Mark Taylor Co-Founder & CEO | 34 patents Topical antifungal nail (onychomycosis) treatment formulations and delivery methods. | — |
| 31 | Aptitude Medical Democratizing diagnostics with accessible, lab-quality molecular testing solutions | $25M | 15 mo ago | 17 | 2011 | Qiang Gong Co-Founder | — | — |
| 32 | Proxim Diagnostics Developer of a handheld immunodiagnostic device for cardiac vascular diseases | $23M | 38 mo ago | 6 | 2010 | — | — | — |
| 33 | Tomi Environmental Solutions Infection control units for surface and environment hygiene | $20M | 31 mo ago | 30 30 → 30 (+0%) · sector median +22% | 2007 | — | 15 patents Ionized hydrogen peroxide and ultrasonic cavitation decontamination for medical equipment | 2 launchs |
| 34 | Okogen Developing ophthalmic anti-viral drugs for adenoviral conjunctivitis (pink eye) | $16M | 18 mo ago | 3 | 2015 | Eric Daniels Founder & COO | 23 patents Patents concentrated in health & consumer products | — |
| 35 | CrossLife Technologies Innovating molecular diagnostics for better health and saving lives | $16M | 11 mo ago | 6 | 2010 | HyunDae Cho Founder & CEO | — | — |
| 36 | Surf Bio Developer of therapeutics for the treatment of multiple diseases | $16M | 25 mo ago | 4 | 2021 | Jennifer Schneider Md Founder | — | — |
| 37 | KAINOMYX Developer of therapeutic solutions for treating malaria and other parasitic diseases | $16M | 21 mo ago | 9 | 2019 | — | — | — |
| 38 | Lighthouse Pharma Developer of therapeutics for neurology and infectious diseases 11Funding top 46%Talent bottom 49%Tech bottom 45%Global bottom 25% All 5 signals ▾Fundingtop 46% Talentbottom 49% Techbottom 45% Globalbottom 25% Marketbottom 18% Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 11/100 | $15M | 1 mo ago | 4 | 2019 | Casey Lynch Chief Executive Officer | — | 1 job opening |
| 39 | Kryptos Biotechnologies Biotechnology company illuminating complex diseases with innovative diagnostic and life science solutions | $13M | 26 mo ago | 7 | 2017 | Jinyong Lee Co-Founder & COO | 47 patents Microfluidic nucleic‑acid extraction and optical PCR sample‑processing platforms | — |
| 40 | Jaguar Health Developing gastrointestinal products for human prescription use and animals 50Product top 14%Funding top 24%Innovation top 34%Growth top 43% All 11 signals ▾Producttop 14% Fundingtop 24% Innovationtop 34% Growthtop 43% Talentbottom 49% Marketbottom 48% Fin. healthbottom 48% Moatbottom 45% Newsbottom 41% Techbottom 33% Globalbottom 32% Product: 4 distinct product lines · Company stage: Public Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $12M | 5 mo ago | 46 46 → 35 (-24%) · sector median +22% | 2013 | Lisa Conte Founder & CEO | — | 1 launch · 1 partnership |
| 41 | Trellis Bioscience Human antibodies against infectious diseases and cancer | $10M | 14 mo ago | 6 | 1998 | Stefan Ryser President & CEO | 170 patents Antibody-based therapeutics and vaccines targeting RSV and influenza viral proteins. | — |
| 42 | Centivax Provider of drug discovery services 55Growth top 25%News top 28%Funding top 32%Patents top 32% All 9 signals ▾Growthtop 25% Newstop 28% Fundingtop 32% Patentstop 32% Innovationtop 40% Moattop 47% Globalbottom 40% Techbottom 39% Marketbottom 29% Growth: Fresh capital in last 24 mo News: 5 BI events in 12 mo (of 5 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $10M | 2 mo ago | 19 | 2019 | — | 39 patents Peptide-derived therapeutic antibodies and low-dose vaccine formulations targeting viral antigens | — |
| 43 | IncellDx Single-cell diagnostics company advancing precision medicine through innovative technology | $9M | 23 mo ago | 24 | 2009 | Bruce Patterson CEO | 96 patents Molecular diagnostics and personalized therapeutics for viral and post‑infectious diseases | — |
| 44 | Granza Bio Developer of therapeutics for the treatment of cancer | $8M | 23 mo ago | — | 2023 | Ashwin Nandakumar Co-Founder & CEO | — | 1 award |
| 45 | Tega Therapeutics Glycoscience company developing heparan sulfate therapies and enzyme replacement therapy | $4M | 6 mo ago | 7 | 2013 | — | — | — |
| 46 | Flow Pharma Developer of immunotherapy platform for infectious disease prevention and cancer therapy | $4M | 22 mo ago | 18 | 2002 | Reid Rubsamen Founder & CEO | — | — |
| 47 | MicroQuin Developer of therapies for treating multiple diseases | $2M | 13 mo ago | 4 | 2016 | Scott Robinson Founder | 13 patents Peptide-based anticancer therapeutics and substituted chalcone small‑molecule drugs | — |
| 48 | Celestial Therapeutics Developer of mRNA-based vaccines and therapies for multiple diseases | $1M | 13 mo ago | — | 2019 | Leontis Teryazos Co-Founder | — | — |
| 49 | Planet Biotechnology Plant-based antibody therapeutics and preventative products for underserved medical needs | $761K | 13 mo ago | 5 | 1994 | Elliott Fineman President and CEO | 42 patents Engineered Fc‑fusion biologics for viral entry inhibition and immune modulation | — |
| 50 | Aethlon Medical Immunotherapeutic device company combating cancer and life-threatening viral infections | $300K | 6 mo ago | 14 14 → 25 (+79%) · sector median +22% | 1999 | Charles Fisher CEO | — | — |
Top 12 Infectious Diseases companies in California
#1
Public · Emeryville, California · founded 2000 · 33 employees$219.5Mraised▾
Public · Emeryville, California · founded 2000 · 33 employees
Developer of eye care and wound care products. The company's products include Avenova An antimicrobial lid and lash solution for eye care, PhaseOne and NeutroPhase a wound care products using hypochlorous acid for cleansing, irrigation, and treating injuries.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 21%Product
top 35%News
top 46%Talent
bottom 49%Moat
bottom 44%Market
bottom 43%Funding: Raised $220M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Post IPO (Jan 2026)
Product: 0 product launch events in 12 mo · Company stage: Public
News: 5 BI events in 12 mo (of 130 tracked, 11 types) · -62% YoY · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 6k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Jan 2026Post IPO$134M
- Aug 2025Post IPO$6M
- Mar 2024Post IPO$665K
- Sep 2022Post IPO—
Founders & team
Investors
Wealthking Investments, TRITON FUNDS, Framework Ventures, Tether, R01 Fund, City Hill
Tech stack
WordpressMysqlPhpYoast SeoNginxPrettyphoto
#2
Public · Menlo Park, California · founded 2017 · 35 employees$92Mraised▾
Public · Menlo Park, California · founded 2017 · 35 employees
Developer of drugs for treating infectious disease. The company is developing novel small molecule therapeutics, designing and executing clinical trials on experimental treatments, and navigating the regulatory approval process for new medicines.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 19%Talent
top 38%Moat
top 48%Market
bottom 42%Global
bottom 32%News
bottom 24%Funding: Raised $92.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Post IPO (Mar 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers · 50 engagements/post (5.8× cohort median)
Activity (LinkedIn): 1 partnerships (incl. GSK for TB) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$40M
- Jan 2022Series B$80M
- Nov 2019Series A$12M
Founders & team
Investors
Mountain Group Partners, Adjuvant Capital, Brii Biosciences, BioRock Ventures, RA Capital Management, BVF Partners
#3
Public · Carlsbad, California · founded 2017 · 55 employees$40Mraised▾
Public · Carlsbad, California · founded 2017 · 55 employees
Provider of rapid point-of-care diagnostic test solutions. It offers FebriDx a rapid, fingerstick blood test intended to help differentiate between bacterial vs non-bacterial acute respiratory infections and ViraDx a rapid POC test that can simultaneously test for respiratory viruses like COVID-19 and Influenza A/B.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 25%Partners
top 31%News
top 34%Growth
top 38%Market
top 48%Moat
top 48%Funding: Raised $40.0M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Post IPO (Mar 2026)
Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
News: 6 BI events in 12 mo (of 21 tracked, 8 types) · +0% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 10k LinkedIn followers — 3.8% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. CG Life) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$20M
- Oct 2020Series B$25M
- Feb 2020Series A$15M
Investors
Ellerston Capital, Perennial, Planet Innovation, AirTree
Tech stack
AkismetBootstrapCloudflareCloudflare Browser InsightsContact Form 7Google Analytics
#4
Series B · Santa Barbara, California · founded 2006 · 21 employees$31.3Mraised▾
Series B · Santa Barbara, California · founded 2006 · 21 employees
Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Moat
top 31%Talent
bottom 49%Patents
bottom 46%Innovation
bottom 39%Global
bottom 36%Funding: Raised $31.3M across 17 rounds · 17 rounds over 13 yrs (1.3/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 12 patents
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Mar 2026Post IPO$2.3M
- Nov 2024Series B$14.4M
- Jun 2024Series A$3.7M
- Nov 2023Series A$2.4M
Founders & team
Investors
National Science Foundation
#5
Series D · San Clemente, California · founded 2013 · 13 employees$110.8Mraised▾
Series D · San Clemente, California · founded 2013 · 13 employees
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections. The company lead product VT-X7 is for Periprosthetic joint infection and targets chronic bacterial PJI. Another drug candidate A-103 is for fungal PJI. The company offers its drug-device combination product for antibiotic therapy for local delivery to treat infected joint prostheses like bacterial and fungal infections for joints like shoulder, knee, and hip.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%Moat
top 38%Talent
bottom 49%Global
bottom 37%Market
bottom 31%Funding: Raised $111M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 5/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 4k LinkedIn followers
Hiring (LinkedIn): 9 hiring posts in 12 mo (public) · momentum +9 · hiring: Area Vice President (East/West), Account Manager
Funding rounds
- Oct 2025Series D$15.6M
- May 2024Series D$50M
- Sep 2023Series C$23M
- Mar 2022Series B$30M
Founders & team
Investors
Gideon Strategic Partners, Johnson & Johnson Innovation – JJDC, Prism Ventures, Medvest Capital, HM Venture Partners, Huimei Capital
#6
Series A · San Francisco, California · founded 2019 · 4 employees$15.2Mraised▾
Series A · San Francisco, California · founded 2019 · 4 employees
Developer of therapeutics for neurology and infectious diseases. It offers a pipeline of drug candidates which include LHP588, is a next-generation gingipain inhibitor for gingivalis infection which causes Alzheimer's disease, Parkinson's disease, and oral dyslapsia. It also offers LHP852 for gingivalis infection and LHP803 for coronavirus infection.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 46%Talent
bottom 49%Tech
bottom 45%Global
bottom 25%Market
bottom 18%Funding: Raised $15.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Tech: 13 technologies across 4/8 capability areas · Cloud: Google Cloud, Google Cloud Cdn · Observability: Sentry
Audience (LinkedIn): 705 LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CTA/Sr. CTA
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. Lighthouse Pharmaceuticals, Inc.) announced in 12 mo
Funding rounds
- Apr 2026Series A$15.2M
Founders & team
Investors
Double Point Ventures
Tech stack
BootstrapGoogle CloudGoogle Cloud CdnGsapHstsHttp/3
#7
Series A · San Francisco, California · founded 2019 · 19 employees$10Mraised▾
Series A · San Francisco, California · founded 2019 · 19 employees
Provider of drug discovery services
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Growth
top 25%News
top 28%Funding
top 32%Patents
top 32%Innovation
top 40%Moat
top 47%Growth: Fresh capital in last 24 mo
News: 5 BI events in 12 mo (of 5 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Capital raise
Funding: Raised $10.0M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) · Last round Series A (Mar 2026)
Funding rounds
- Mar 2026Series A$37M
- Jul 2025Series A$45M
- Jul 2025Grant (prize money)$24M
- Nov 2022Seed$10M
Investors
NFX, Global Health Investment, HHS, Future Ventures, Bold Capital Partners, Kendall Capital Partners
Tech stack
AngularCart FunctionalityCore-JsGoogle WorkspaceHstsModernizr
#8
Public · San Diego, California · founded 2009 · 126 employees$100Mraised▾
Public · San Diego, California · founded 2009 · 126 employees
Developer of sexual and reproductive health therapeutics. It offers two drug products which include PHEXXI vaginal gel that provides women with an in-the-moment contraceptive that maintains the baseline vaginal pH environment and SOLOSEC (secnidazole) which is used to treat bacterial vaginosis in women and the STI trichomoniasis in both men and women.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 24%Product
top 30%Moat
top 38%Patents
top 43%Fin. health
top 46%Innovation
top 48%Funding: Raised $100M across 15 rounds · 15 rounds over 17 yrs (0.9/yr) · Last round Post IPO (Jun 2025)
Product: 1 distinct product line · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 60 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 10k LinkedIn followers — 4.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Clavi Davis Pharmaceuticals) announced in 12 mo
Funding rounds
- Jun 2025Post IPO$925K
- Apr 2025Post IPO$750K
- Sep 2023Post IPO$2.9M
- Feb 2023Post IPO$1.4M
Founders & team
Investors
Woodford Investment Management, Invesco Mutual Fund, Adjuvant Capital, Keystone Capital, Walleye, Pinz Capital Management
#9
Public · San Francisco, California · founded 2013 · 46 employees$11.6Mraised▾
Public · San Francisco, California · founded 2013 · 46 employees
Jaguar Health is engaged in developing novel, sustainably derived gastrointestinal products for humans and animals. The company focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Canalevia is the company's lead animal prescription drug product candidate intended for the treatment of various forms of diarrhea in dogs and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Product
top 14%Funding
top 24%Innovation
top 34%Growth
top 43%Talent
bottom 49%Market
bottom 48%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) · Last round Grant (prize money) (Jan 2026)
Innovation: 4 product lines
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Japan Health and Filament Health) announced in 12 mo
Funding rounds
- Jan 2026Grant (prize money)$240K
- Sep 2025Post IPO$2.4M
- Feb 2023Post IPO—
- Jul 2022Post IPO$300K
Founders & team
Investors
Sagard Holdings, Hercules Capital, Napo Pharma, FDA
Tech stack
WordpressMysqlPhpBootstrapYoast SeoNginx
#10
Public · San Francisco, California · founded 2018 · 70 employees$225Mraised▾
Public · San Francisco, California · founded 2018 · 70 employees
Aligos Therapeutics has developed small molecule-based therapeutics for the treatment of hepatologic diseases and viral infections. The drugs target viral nucleic acids, encoded proteins, oncogenes, and resultant proteins for the treatment. It has developed drugs to treat chronic hepatitis B, nonalcoholic steatohepatitis, and hepatocellular carcinoma.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 12%Innovation
top 16%Funding
top 26%Moat
top 35%Partners
top 40%Tech
top 42%Patents: 503 patents matched (strict assignee match) · 389 filings since 2022 vs 114 in 2017-21 · Latest publication 2026
Innovation: 503 patents (top 5% of patent-holders) · 389 filings since 2022 vs 114 in 2017-21
Funding: Raised $225M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) · Last round Post IPO (Feb 2025)
Audience (LinkedIn): 7k LinkedIn followers — 3.0% of this cohort's audience
Funding rounds
- Feb 2025Post IPO$105M
- Oct 2023Post IPO$92.2M
- Jan 2020Series B$125M
- 2018Series A$100M
Founders & team
Investors
Wellington, Boxer Capital, Logos, Vivo Capital, Novo Holdings, Roche
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#11
Series B · San Mateo, California · founded 2019$37Mraised▾
Series B · San Mateo, California · founded 2019
Developer of therapies for the treatment of chronic hepatitis B and other major infectious diseases. It offers a pipeline of oligonucleotide therapeutics, including AHB-137 based on conjugation technology for targeted delivery and integrating DNA replication inhibitors, HBsAg inhibitors, and immunomodulators.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 26%Talent
top 38%Moat
top 39%Growth
bottom 42%Market
bottom 40%Global
bottom 38%Funding: Raised $37.0M across 4 rounds · 4 rounds over 2 yrs (2.0/yr) · Last round Series B (Sep 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 986 LinkedIn followers
Funding rounds
- Sep 2025Series B$63M
- May 2025Series B$50M
- Dec 2024Series B$73M
- Jul 2024Series A$37M
Founders & team
Investors
Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, Genesis Capital, InnoPinnacle Fund, Sherpa Capital
#12
Series D · Menlo Park, California · founded 2014 · 55 employees$141.1Mraised▾
Series D · Menlo Park, California · founded 2014 · 55 employees
Provider of food safety technologies for the identification of pathogens. The company offers Clear Dx, a rapid, high throughput next-generation sequencing (NGS) platform for clinical and public health labs that offers a complete characterization of SARS-CoV-2.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Patents
top 19%Funding
top 22%Innovation
top 28%Moat
top 28%Growth
top 32%Talent
top 41%Patents: 79 patents matched (strict assignee match) · 40 filings since 2022 vs 25 in 2017-21 · Latest publication 2026
Funding: Raised $141M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Series D (Dec 2024)
Innovation: 79 patents (top 23% of patent-holders) · 40 filings since 2022 vs 25 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Dec 2024Series D$30M
- May 2021Series C$60M
- May 2020Series B$39.5M
- Apr 2019Series B—
Founders & team
Investors
Google Ventures, Menlo Ventures, Khosla Ventures, Redmile Group, Wing Venture Capital, Dentsu
Tech stack
Apple Icloud MailGodaddyGoogle AnalyticsGoogle Tag ManagerGoogle WorkspaceJquery
Funding & investor landscape
$6.8Btotal disclosed funding
154companies funded
774disclosed rounds
3rounds last 90 days
Most active investors
Gates9 rounds
Notable founders
Justin Hall
CEO · NovaBay Pharmaceuticals
Eric Easom
Co-Founder & CEO & President · AN2 Therapeutics
Michael Alley
Co-Founder · AN2 Therapeutics
Ken Babcock
CEO · Affinity Biosensors
David Thompson
Chairman and Chief Executive Officer · Osteal Therapeutics
Casey Lynch
Chief Executive Officer · Lighthouse Pharma
Saundra Pelletier
CEO ► Phexxi ► Solosec · Evofem
Lisa Conte
Founder & CEO · Jaguar Health
Lawrence Blatt
CEO · Aligos Therapeutics
Margarita Chavez
Board Member · Aligos Therapeutics
Guofeng Cheng
Co-Founder & CEO · AusperBio
Chris Yang
Co-Founder & CSO · AusperBio
Prism market signals · United States · country-scoped Prism corpus, 1,265,774 docs
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
RESEARCH IN CALIFORNIA · Health & Bio
How research on Diagnostics in California is moving
A read on the academic research around Diagnostics in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 758 papers.
UC San Francisco, UCLA, and USC lead California's diagnostics research, predominantly advancing cancer genomics and biosensors with an optimistic tone, though concern papers signal emerging tensions.
758 papers · stance +0.40 · 27% breakthrough · 24% concern
top institutions
- University of California, San Francisco159
- University of California, Los Angeles138
- University of Southern California106
- University of California, San Diego77
- University of California, Davis72
leading researchers
Gerald J. Kost · Liya Xu · David T. Wong · Stephanie N. Shishido · Corbin M. Curtis · Hyou‐Arm Joung
prism intelligence · tone & topics
90% positive · 6% critical tone
HealthcareHealthBiotechnologyPharmaceuticalsClinical TrialsMedical Research
▲
Breakthroughs181 · 24%
▲ 20%→25% share
▲1.2× share momentum3 median citations47% since 2021mostly methods-led
Liquid biopsy breakthroughs are surging — papers nearly tripled from 17 to 42 in California diagnostics research.
rising sub-themes (early→recent)
- Liquid biopsy17→42
- Point-of-care testing9→23
- Biopsy1→14
- Point of care8→16
- Computational biology3→9
Newly emergingDetection limit 0→6 · Retinoblastoma 0→6 · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 0→5
Landmark Integrated rapid-diagnostic-test reader platform on a cellphone · 417 cites
◆
Advancements335 · 44%
▲ 43%→45% share
▲1.0× share momentum6 median citations46% since 2021mostly empirical
Biopsy advancement research intensifying — papers quadrupled from 7 to 31, with pathology newly scaling to 12.
rising sub-themes (early→recent)
- Liquid biopsy33→58
- Biopsy7→31
- Pathology1→12
- Circulating tumor cell15→25
- Breast cancer3→12
Newly emergingCerebrospinal fluid 0→6 · Colorectal cancer 0→6 · Microvesicles 0→5
Landmark Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma · 599 cites
▼
Concerns163 · 22%
▼ 23%→22% share
▲1.0× share momentum11 median citations47% since 2021mostly empirical
Liquid biopsy concern papers rose sixfold from 4 to 24, signaling growing scrutiny of clinical reliability.
rising sub-themes (early→recent)
- Liquid biopsy4→24
- Biomarker1→9
- Intensive care medicine3→7
- Tuberculosis1→4
- Incidence (geometry)1→4
Newly emergingBiopsy 0→9 · Coronavirus disease 2019 (COVID-19) 0→6 · Circulating tumor DNA 0→4
Landmark LAMP Diagnostics at the Point-of-Care: Emerging Trends and Perspectives for the Developer Community · 269 cites
Common questions
How many Infectious Diseases companies are there in California, United States?
Radar tracks 238 indexable Infectious Diseases companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Infectious Diseases companies in California, United States?
The Infectious Diseases companies in California, United States on this list have raised a combined $6.8B in disclosed equity funding across 154 funded companies.
Which is the highest-funded Infectious Diseases company in California, United States?
Brii Biosciences is the highest-funded Infectious Diseases company in California, United States, with $515M in disclosed equity funding.
How many Infectious Diseases companies in California, United States are funded?
154 of the 238 Infectious Diseases companies in California, United States on this list have disclosed at least one equity funding round.
How many Infectious Diseases unicorns are there in California, United States?
None of the Infectious Diseases companies in California, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in California, United States Infectious Diseases companies?
The most active investors in California, United States Infectious Diseases companies on this list include HHS, Frazier Healthcare Partners, Gates, Military Health, NIH.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.